Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scar wars: is TGFbeta the phantom menace in scleroderma?

Andrew Leask1

  • 1Division of Oral Biology and Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, Dental Sciences Building, London, ON N6A 5C1, Canada. Leask@schulich.uwo.ca

Arthritis Research & Therapy
|June 16, 2006
PubMed
Summary

Scleroderma (systemic sclerosis) causes tissue scarring, but its cause is unknown. New research reveals transforming growth factor-beta (TGFbeta) pathways as potential targets for anti-fibrotic therapies in scleroderma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interview with Neha Dinesh, American Society for Matrix Biology Founders Award Recipient.

Matrix biology : journal of the International Society for Matrix Biology·2026
Same author

Crosstalk of the Hippo/YAP pathway in the progression of oral potentially malignant disorders to oral squamous cell carcinoma: a systematic review.

Frontiers in oral health·2026
Same author

SYISL promotes pulmonary epithelial-mesenchymal transition and fibrosis through DSP-Hippo/YAP pathway.

Cellular and molecular life sciences : CMLS·2026
Same author

A Pan-Cancer Transcriptomic Signature for Conserved Molecular Programs Underlying Premalignant-Malignant Progression Across Common Carcinomas.

Dentistry journal·2026
Same author

CCN1: a SASPy protein that plays multifaceted roles in fibrogenesis.

Matrix biology : journal of the International Society for Matrix Biology·2025
Same author

The Areca Nut and Oral Submucosal Fibrosis: A Narrative Review.

Dentistry journal·2025

Area of Science:

  • Immunology
  • Fibrosis Research
  • Rheumatology

Background:

  • Scleroderma (systemic sclerosis, SSc) is an autoimmune disease marked by widespread tissue fibrosis.
  • Current treatments do not address the underlying fibrotic scarring in SSc.
  • The exact cause of fibrosis in SSc remains unknown.

Purpose of the Study:

  • To explore the role of transforming growth factor-beta (TGFbeta) signaling in SSc fibrosis.
  • To identify potential therapeutic targets for anti-fibrotic drug intervention in SSc.

Main Methods:

  • Elucidation of TGFbeta signaling pathways involved in fibrotic processes.
  • Analysis of molecular mechanisms driving pathological scarring in SSc.

Main Results:

Related Experiment Videos

  • Recent advances have clarified how TGFbeta signaling activates fibrotic programs.
  • Several specific intervention points within the TGFbeta pathway have been identified.

Conclusions:

  • TGFbeta signaling is a key driver of fibrosis in SSc.
  • These findings open new avenues for developing anti-fibrotic therapies for scleroderma.